Uterine Corpus Cancer Subcommittee

Committee Charge

The NRG Oncology Uterine Corpus Cancer Subcommittee’s purpose is to improve the live of patients with uterine cancer by designing and conducting practice-changing multi-institutional clinical trials and translational research. This committee focuses on developing and testing innovative advanced surgical, radiation oncology, and systemic (including chemotherapy and other targeted/biologic therapies) technologies for patients with gynecologic uterine malignancies. Additionally, the committee is committed to identifying and rectifying disparities in patient outcomes within this population.

The goals of this committee include developing national and international priorities, goals, and initiatives for the management of uterine cancer; developing and managing currently active and developing NRG clinical trials on the prevention, diagnosis, and treatment of uterine corpus cancers; and, fostering the advancement of promising therapeutics in development and exploring potential translational research and biomarker development for incorporation into future clinical trials. This committee strives to develop and implement standardized procedures needed to design and conduct a research protocol within NRG while identifying potential barriers, and potential solutions to improve enrollment to NRG clinical trials in uterine corpus cancers, including fostering international collaboration. This committee meets four times a year, twice in-person and two virtual interim meetings.